93413-76-4

Basic information

• Product Name: 1-[Cyano-(p-methoxyphenyl)methyl]cyclohexanol
• Synonyms: alpha-(1-Hydroxycyclohexyl)-4-methoxybenzeneacetonitrile;1-(Hydroxycyclohexyl)-(4-Methoxyphenly)Acetonitrlle;1-[(1-CYANO)-1-(4-METHOXYPHENYL)METHYL]CYCLODEXANOL;1-[Cyno-(4-Methoxyphenyl)Methyl]Cyclohexanol(Vf1);1-HydroxyCyclohexyl-4-MethoxyPhenylAcetonitrile(ForVenlafaxineHcl);forVenlafaxine;Intermediate of Venlafaxine;1-[Cyano-(4-Methoxyphenyl)Meth
• CAS NO: 93413-76-4
• Molecular Formula: C₁₅H₁₉NO₂
• Molecular Weight: 245.32
• EINECS: 1533716-785-6
• Product Categories: Medicine intermediate;Nitriles;API intermediates;(intermediate of venlafaxine);(intermediate of venlafaxine hcl);Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 93413-76-4.mol
• Article Data: 35

Chemical Properties

• Melting Point: 121-123°C
• Boiling Point: 410.146 °C at 760 mmHg
• Flash Point: 201.849 °C
• Appearance: white powder
• Density: 1.142 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 0-10°C
• Solubility: soluble in Methanol
• PKA: 13.80±0.20(Predicted)
• CAS DataBase Reference: 1-[Cyano-(p-methoxyphenyl)methyl]cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[Cyano-(p-methoxyphenyl)methyl]cyclohexanol(93413-76-4)
• EPA Substance Registry System: 1-[Cyano-(p-methoxyphenyl)methyl]cyclohexanol(93413-76-4)

Safety Data

• Hazardous Substances Data: 93413-76-4(Hazardous Substances Data)

Usage

Synthesis

A mixture of p-methoxyphenylacetonitrile 36 (100 g, 0.68 mol), 10% aqueous NaOH solution (100 ml, 0.25 mol) and TBAHSO4 (5 g, 0.014 mol) was stirred at room temperature for 30 minutes. A dark red colour appeared. To this was added cyclohexanone 34 (67 g, 0.680 mol) in small portions at 0 oC, with vigorous stirring, in such a way that temperature should not rise above 10 oC. A white solid was formed within 30 minutes to one hour. The solid was crushed and the reaction mixture was further stirred vigorously at room temperature for one more hour. The solid was filtered, washed with water till neutral to pH paper and air-dried. Crystallization from ethyl acetatepetroleum ether (500:350, v/v) gave a bright white solid (161.66 g).

Chemical Properties

White Powder

InChI:InChI=1/C15H19NO2/c1-18-13-7-5-12(6-8-13)14(11-16)15(17)9-3-2-4-10-15/h5-8,14,17H,2-4,9-10H2,1H3

Upstream product

• 104-47-2 p-methoxybenzylnitrile 
• 108-93-0 cyclohexanol 
• 108-94-1 cyclohexanone 
• 874-90-8 4-methoxybenzonitrile 

Downstream Products

• 93413-69-5 1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]cyclohexanol 
• 130198-05-9 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride 
• 93413-77-5 N,N-didesmethylvenlafaxine 
• 99300-78-4 venlafaxine hydrochloride 
• 55-81-2 4-Methoxyphenethylamine 
• 149289-29-2 N,N-Didesmethyldesvenlafaxine 
• 93413-90-2 N-Desmethylvenlafaxine hydrochloride 
• 272788-07-5 N-[2-(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)ethyl]formamide 

Relevant articles and documents

Method for industrially producing venlafaxine hydrochloride

The invention discloses a method for industrially producing venlafaxine hydrochloride, and relates to the technical field of drug organic synthesis. The method has the advantages of easily available raw materials of the whole synthetic route, mild reaction conditions, simple and convenient operation, high yield, environment friendliness and good repeatability of the preparation method, and can be used for preparing venlafaxine hydrochloride with high yield and high purity.

SUBSTITUTED ARYLUREA COMPOUNDS FOR INDUCING APOPTOSIS AND COMPOSITION FOR ANTICANCER COMPRISING THE SAME

The present invention relates to a substituted arylurea compound inducing apoptosis and an anticancer composition comprising the same. The present invention relates to a novel compound capable of preventing, treating and alleviating cancer diseases such as prostate cancer, breast cancer, lung cancer, colorectal cancer, and skin cancer by inhibiting apoptosis of cancer cells and inhibiting proliferation of cancer cells.

Method for preparing pharmaceutical intermediate with hydrotalcite material by catalysis

The invention belongs to the technical field of medicine, and particularly relates to a method for preparing a pharmaceutical intermediate with a hydrotalcite material by catalysis. The method includes first utilizing lithium fluoride as a modifier to modify the Zn/Al hydrotalcite material to obtain a hydrotalcite-supported lithium fluoride material. The hydrotalcite-supported lithium fluoride material can catalyze 4-methoxybenzyl cyanide and cyclohexanone to have condensation reaction to prepare 1-hydroxycyclohexyl-4-methoxybenzyl cyanide. The defects in the prior art of harsh reaction conditions, low yield and high environment pollution in the preparation process of overcomes the harsh reaction conditions in the preparation of a PRISTIQ and/or venlafaxine framework are overcome.